𩺠å
§ç§å°ç§èåç
1ïžâ£ PROCAMIO Trial (Procainamide vs Amiodarone for Stable Sustained VT)
- Procainamide superior in terminating VT
- Less hypotension than amiodarone IV
- Preferred for stable monomorphic VT (without HF)
- Amiodarone alternative
2ïžâ£ CASTLE-HF (Ablation in HFrEF + AF)
- Different from VT ablation
- But underscores ablation role in HF context
3ïžâ£ ICD Decision-Making in HFrEF
- EF †35% on optimal medical therapy ⥠3 months (not ⥠1 month after MI; not first 40 days post-MI per DINAMIT)
- Reassess EF after optimization
- Wearable cardioverter defibrillator (LifeVest) as bridge in select
- Patient preference + life expectancy + comorbidities
4ïžâ£ HCM SCD Risk Factors
- Family hx SCD (especially < 50 yr)
- Recent unexplained syncope
- NSVT on Holter
- LV wall thickness ⥠30 mm
- Abnormal BP response to exercise (failure to rise > 25 mmHg)
- Extensive LGE on cardiac MRI
- Combined risk stratification + ICD decision
5ïžâ£ CPVT Management
- β-blockers (nadolol) + flecainide (calcium handling)
- Exercise restriction
- ICD for refractory
- Left cardiac sympathetic denervation (LCSD) for refractory â surgical removal of stellate ganglion + thoracic sympathetic chain on left
6ïžâ£ Brugada Syndrome
- Type 1 (coved) â diagnostic
- Type 2 (saddle-back) â suggestive; provocative test (procainamide, ajmaline, flecainide IV)
- Avoid drugs unmasking Brugada (sodium channel blockers, propofol)
- ICD for symptomatic or family hx SCD
- Avoid fever (febrile illness â cooling + Tx underlying)
7ïžâ£ ARVC Management
- Family screening (first-degree relatives)
- Exercise restriction (especially competitive)
- ICD for high-risk features
- Anti-arrhythmic drugs (sotalol, amiodarone, flecainide)
8ïžâ£ Familial SCD Screening
- First-degree relatives of SCD victims
- ECG + echo + cardiac MRI + Holter + exercise test
- Genetic testing for known mutations
- Refer to cardiogenetic specialty
- Risk stratification + family counseling
9ïžâ£ å¥ä¿ / Taiwan
- å¥ä¿ ICDs covered for indications
- Catheter ablation widely available
- Genetic testing limited (é« cost)
- Specialized arrhythmia centers in tertiary
10. Future + Innovations
- Subcutaneous + leadless ICDs
- Pulsed field ablation (PFA) for VT (safer + faster)
- AI for ECG-based SCD risk prediction
- Genetic-guided treatment decisions
- Wearables + remote monitoring for high-risk